Differentiating hyperlipidaemia associated with antiretroviral therapy

Area of Science:

• Cardiovascular Health
• HIV Medicine
• Lipid Metabolism

Background:

• Antiretroviral therapy (ART) in HIV patients can cause hyperlipidaemia, raising concerns about increased cardiovascular risk.
• Understanding the specific lipoprotein abnormalities in HIV-infected individuals is crucial for risk assessment.

Purpose of the Study:

• To compare the lipoprotein patterns of HIV-positive patients, both on and off ART, with those of patients diagnosed with familial combined hyperlipidaemia (FCH) and familial hypertriglyceridaemia (FHT).
• To elucidate the nature of dyslipidaemia in HIV patients and its relation to cardiovascular risk.

Main Methods:

• Serum samples were collected from HIV-infected patients and individuals with specific familial lipid disorders.
• Analysis included total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides, apolipoprotein A1, and apolipoprotein B.
• Very low-density lipoprotein (VLDL) was isolated and analyzed for its lipid and apolipoprotein content.

Main Results:

• A significant proportion (61%) of HIV-positive patients exhibited lipoprotein disorders, predominantly type IV (elevated VLDL-cholesterol).
• In HIV patients with type IV hyperlipidaemia, the ratio of VLDL-triglycerides to VLDL-apolipoprotein B was similar to patients with FHT.
• This VLDL particle characteristic differed significantly from that observed in patients with FCH.

Conclusions:

• HIV-infected patients with elevated VLDL display large VLDL particles, a pattern characteristic of FHT, not FCH.
• The findings suggest that the VLDL abnormalities in HIV-infected individuals may confer a cardiovascular risk profile distinct from FCH.
• Further research is warranted to fully understand the contribution of VLDL-associated hypercholesterolaemia in patients on ART to their overall cardiovascular risk.